T-Cell Prolymphocytic Leukemia: An Experience from a Tertiary Cancer Centre in South India

Background: T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoid malignancy with dismal prognosis. Most patients have increased lymphocyte count (>1,00,000/dL) and widespread disease at presentation. Despite high response rate seen with alemtuzumab, the disease relapse is inevitable. Materia...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology- oncology and stem cell research 2018-04, Vol.12 (2), p.132-135
Main Authors: Babu MC, Suresh, Anand, Abhishek, Lakshmaiah, Kuntegowdanahalli C., Babu K, Govind, Lokanatha, Dasappa, Jacob, Linu Abraham, Madhumathi, DS, Lokesh, Kadabur N, Rudresha, AH, Rajeev, LK, Patidar, Rajesh
Format: Article
Language:English
Subjects:
Alemtuzumab
Original
Prolymphocytic leukemia
T-cells
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoid malignancy with dismal prognosis. Most patients have increased lymphocyte count (>1,00,000/dL) and widespread disease at presentation. Despite high response rate seen with alemtuzumab, the disease relapse is inevitable. Materials and Methods : This was a retrospective observational study done at a tertiary cancer center in South India. All patients diagnosed with T-PLL from August 2010 to July 2015 were studied for the clinical characteristics, pathological findings and treatment outcomes. Results : Seven patients were diagnosed as T-PLL over a period of 5 years. The median age at diagnosis was 51 years. In the present series, 6 patients (86%) had splenomegaly and 3 had hepatomegaly (43%). Generalized lymphadenopathy was seen in 4 (57%) patients at presentation. Skin lesions were seen in 5 (71%) patients, whereas pleural effusion was seen in only one patient (14%). All had elevated total leukocyte count, with more than 1, 00,000/dL in 4 patients. The median survival was 5 months with different chemotherapy (CT) regimens (5 patients treated with CT and 2 received best supportive care). Conclusion: T-PLL is a rare disease with no definite treatment guidelines. At present, the best outcomes are achieved if treatment with alemtuzumab is followed by stem cell transplant, but the disease invariably relapses. Countries where affordability remains a big challenge, the best approach needs to be defined beyond the monoclonal antibodies and transplant.
ISSN:2008-3009
2008-2207